ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC.Clinical epigenetics · 2026Article
- Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025Review
- Review
- The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.Journal of biological engineering · 2024Review
- Establishment of an orthotopic model of lung cancer by transthoracic lung puncture using tumor fragments.Journal of thoracic disease · 2023Article
- Lack of racial and ethnic diversity in lung cancer cell lines contributes to lung cancer health disparities.Frontiers in oncology · 2023Review
- Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.Frontiers in immunology · 2023Review
- Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Lung Cancer Computational Biology and Resources.Cold Spring Harbor perspectives in medicine · 2022Review
- Article
- Review
- Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories.Open biology · 2021Review
- Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Neuroendocrine Lung Cancer Mouse Models: An Overview.Cancers · 2020Review
- Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model.Scientific reports · 2020Article
- Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation.Nature communications · 2020Article
- Intensive care for human hearts in pluripotent stem cell models.NPJ Regenerative medicine · 2020Review
- Recent progress in mapping the emerging landscape of the small-cell lung cancer genome.Experimental & molecular medicine · 2019Review
- Concomitant deletion of HRAS and NRAS leads to pulmonary immaturity, respiratory failure and neonatal death in mice.Cell death & disease · 2019Article
- A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography.Scientific reports · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionStudies of preclinical models are essential for determining the biology of lung cancers and testing new and novel therapeutic approaches. We review the commonly used preclinical models for lung cancers and evaluate their strengths and weaknesses.
methodsWe searched the MEDLINE database via PubMed using combinations of the following medical subject headings: lung cancer; animal models, mice; cell line, tumor; cell culture, mice; transgenic, mice; SCID, transplantation; heterologous; and genetic engineering. We reviewed the relevant published articles.
resultsMultiple examples of the three major preclinical models-tumor cell lines, patient-derived xenografts, and genetically engineered mouse models-exist and have been used by investigators worldwide, with more than 15,000 relevant publications. Each model has its strengths and actual or potential weaknesses. In addition, newer forms of these models have been proposed or are in use as potential improvements over the conventional models.
conclusionsA large number and variety of models have been developed and extensively used for the study of all major types of lung cancer. While they remain the cornerstone of preclinical studies, each model has its individual strengths and weaknesses. These must be carefully evaluated and applied to the proposed studies to obtain the maximum usefulness from the models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.